Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
RU 24969 hemisuccinateCat. No. 0912 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 5-Methoxy-3-(1,2,5,6-tetrahydro-4-pyridinyl)-1H-indole hemisuccinate |
Biological Activity
Potent 5-HT1A/1B and moderate 5-HT2C agonist that may also release 5-HT. Centrally active following systemic administration.Certificate of Analysis / Safety Data Sheet
References
Guillaume et al (1987) Synthesis of 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles and study of their serotonergic and antidopaminergic properties. Eur.J.Med.Chem. 22 33.
Gudermann et al (1993) Human S31 serotonin receptor clone encodes a 5-hydroxytryptamine1E-like serotonin receptor. Mol.Pharmacol. 43 412. PMID: 8450834.
Tomkins and O'Neill (2000) Effect of 5-HT1B receptor ligands on self-administration of ethanol in an operant procedure in rats. Pharmacol.Biochem.Behav. 66 129. PMID: 10837852.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: RU 24969 hemisuccinate, supplier, 5-HT1B/1A, agonists, Serotonin, Receptors, RU24969, hemisuccinate, C14H16N2O½C4H6O4
Quick Order
Find multiple products by catalog number
5-HT Review
Written by Nicholas Barnes and John Neumaier, leading experts. Request a copy or view PDF today.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
Tocris Events
Win a Kindle
5th Conference on Advances in Molecular Mechanisms Underlying Neurological Disorders
June 23 - 26, 2013
Bath, UK